Prescient Surgical: Novel Irrigating Wound Retractors Shown to Be Cost Effective in Colorectal Surgery

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 4, 2018

Prescient Surgical announced the publication of economic data in the Journal of Surgical Research that support the cost-effectiveness of CleanCision, its novel irrigating wound retraction and protection system, which is commercially available in the United States and approved for use in Europe.

SSI is the most common and costly of all healthcare-associated infections resulting in an estimated $3.5 to $10 billion annually in healthcare expenditures.1 This is of particular significance in colon surgery, which is associated with the highest rate of SSI among all elective surgical procedures.2 Recent published data shows an SSI in colon surgery can result in additional cost of over $40,000 to the hospital.3

Prescient Surgical advises that the study demonstrated that double-ring devices, particularly the novel irrigating wound retractor, CleanCision, provided superior clinical benefit at lower cost, compared with both previous-generation single-ring wound protection devices and bundled process-based interventions. Substantial health benefits were reported, including 230 quality-adjusted life-years (QALYs) per 1000 patients.

Small reductions in SSI risk leads to substantial cost savings. The study reported that newer innovations like CleanCision that provide continuous irrigation deliver incremental benefits that conservatively could save over $2 million dollars per 1000 patients. The study also concluded that further innovation in device-based wound protection devices may offer increased prevention of SSI at acceptable cost-effectiveness levels.

“This study demonstrates that advanced technology to fight SSI helps hospitals achieve the triple aim of better protecting patients against infection, reducing cost, and advancing the quality of surgical care,” said Jonathan Coe, President and CEO, Prescient Surgical.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.